Therapy Detail

Therapy Name ARQ092
Therapy Description

Miransertib (ARQ092) is a pan-AKT inhibitor, resulting in inhibition of the PI3K/AKT signaling pathway and cell proliferation (PMID: 26469692).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
ARQ092 Miransertib ARQ-092 Akt Inhibitor (Pan) 17 Miransertib (ARQ092) is a pan-AKT inhibitor, resulting in inhibition of the PI3K/AKT signaling pathway and cell proliferation (PMID: 26469692).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AKT1 E17K endometrial cancer sensitive ARQ092 Preclinical - Cell line xenograft Actionable In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ092, demonstrating inhibition of tumor growth (PMID: 26469692). 26469692
Unknown unknown Advanced Solid Tumor not applicable ARQ092 Phase I Actionable In a Phase I trial, ARQ092 demonstrated safety and is currently being tested for efficacy in clinical trials in patients with advanced solid tumors (American Association for Cancer Research. April 6-10, 2013. Abstract #LB-197). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02476955 Phase I ARQ092 Carboplatin + Paclitaxel Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel Recruiting
NCT01473095 Phase I ARQ092 Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma Completed